Aclaris Therapeutics (ACRS) Projected to Post Earnings on Tuesday

Aclaris Therapeutics (NASDAQ:ACRS) is projected to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Aclaris Therapeutics to post earnings of ($0.09) per share and revenue of $7.04 million for the quarter.

Aclaris Therapeutics Stock Performance

Shares of ACRS stock opened at $2.33 on Tuesday. The firm’s 50-day moving average is $2.66 and its 200-day moving average is $2.10. The stock has a market cap of $166.43 million, a price-to-earnings ratio of -4.48 and a beta of 0.50. Aclaris Therapeutics has a 52-week low of $0.95 and a 52-week high of $5.17.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ACRS. BTIG Research upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Tuesday, November 19th. Piper Sandler upgraded shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $3.00 to $13.00 in a research report on Monday, November 18th. StockNews.com cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 8th. HC Wainwright raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Monday, December 23rd. Finally, Jefferies Financial Group raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and raised their target price for the stock from $2.00 to $7.00 in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $11.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.